Literature DB >> 21988290

The importance of the comparator in economic evaluations: working on the efficiency frontier.

Mattias Neyt1, Hans Van Brabandt.   

Abstract

Mesh：

Year:  2011        PMID： 21988290     DOI： 10.2165/11595260-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  9 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  Questions about adjuvant trastuzumab still remain.

Authors:  Daniel Hind; Hazel Pilgrim; Sue Ward
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

3.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

4.  Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.

Authors:  S Ward; H Pilgrim; D Hind
Journal:  Health Technol Assess       Date:  2009-06       Impact factor: 4.014

5.  Economic evaluation of long-term management strategies for erosive oesophagitis.

Authors:  R Goeree; B O'Brien; R Hunt; G Blackhouse; A Willan; J Watson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

6.  Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.

Authors:  Mattias Neyt; Michel Huybrechts; Frank Hulstaert; France Vrijens; Dirk Ramaekers
Journal:  Health Policy       Date:  2008-03-04       Impact factor: 2.980

7.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Petri Bono; Tuomo Alanko; Vesa Kataja; Raija Asola; Tapio Utriainen; Riitta Kokko; Akseli Hemminki; Maija Tarkkanen; Taina Turpeenniemi-Hujanen; Sirkku Jyrkkiö; Martti Flander; Leena Helle; Seija Ingalsuo; Kaisu Johansson; Anna-Stina Jääskeläinen; Marjo Pajunen; Mervi Rauhala; Jaana Kaleva-Kerola; Tapio Salminen; Mika Leinonen; Inkeri Elomaa; Jorma Isola
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

8.  Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context.

Authors:  Mattias Neyt; Nancy Thiry; Dirk Ramaekers; Hans Van Brabandt
Journal:  Appl Health Econ Health Policy       Date:  2008       Impact factor: 2.561

Review 9.  Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials.

Authors:  Simon K H Lam; Andrew Owen
Journal:  BMJ       Date:  2007-10-11
  9 in total
  3 in total

1.  Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.

Authors:  Thitima Kongnakorn; Tereza Lanitis; Lieven Annemans; Vincent Thijs; Marnix Goethals; Sophie Marbaix; Jean-Claude Wautrecht
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

2.  The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator.

Authors:  Mattias Neyt; Ann Van Den Bruel
Journal:  Eur J Health Econ       Date:  2012-08

Review 3.  The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations.

Authors:  Mattias Neyt; Hans Van Brabandt; Carl Devos
Journal:  BMC Cardiovasc Disord       Date:  2013-09-26       Impact factor: 2.298
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.